Bristol-Myers Squibb Co., of New York, said data supporting the clinical development of BMS-955176, an investigational component designed to prevent the maturation of HIV-1, was described in an oral and a poster presentation at the Conference on Retroviruses and Opportunistic Infections in Seattle.